Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease

Daisuke Ito, Mitsuru Murata, Norio Tanahashi, Hideki Sato, Akira Sonoda, Ikuo Saito, Kiyoaki Watanabe, Yasuo Fukuuchi

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background and Purpose - A growing amount of evidence suggests that infectious and inflammatory processes may be involved in the initiation of arteriosclerosis, but the mechanisms are conceivably multifactorial and complex. Two European groups have recently demonstrated that a C(-260)→T polymorphism in the promoter of the CD14 lipopolysaccharide receptor may be a risk factor for coronary artery disease (CAD). The T allele of this polymorphism reportedly increases the expression of CD14 and may be involved in atherogenesis. In the present study we investigated a possible association between the C(-260)→T polymorphism in the CD14 promoter and the occurrence of symptomatic ischemic cerebrovascular disease (CVD). Methods - Genotype frequencies of the C(-260)→T polymorphism in the CD14 promoter were determined in 235 patients with CVD, as confirmed by brain CT and/or MRI, and 309 age- and sex-matched control subjects. Results - The distribution of genotypes was as follows: CVD patients, T/T 24.3%, C/T 53.2%, and C/C 22.6%; controls, T/T 26.9%, C/T 50.2%, and C/C 23.0%. There was no significant difference between the CD14 promoter genotypes of the CVD patients and the controls (χ2=0.601, P=0.741). We also measured the concentration of serum soluble CD14 and the density of membranous CD14 on monocytes in the CVD patients, but the polymorphism was not associated with either the concentration of soluble CD14 or the density of membranous CD14 (P=0.358, P=0.238, respectively). Conclusions - Our results indicate that the C(-260)→T polymorphism in the CD14 promoter is not associated with an increased risk for CVD.

Original languageEnglish
Pages (from-to)2661-2664
Number of pages4
JournalStroke
Volume31
Issue number11
Publication statusPublished - 2000

Fingerprint

CD14 Antigens
Cerebrovascular Disorders
Genotype
Arteriosclerosis
Coronary Artery Disease
Monocytes
Atherosclerosis
Alleles
Brain
Serum

Keywords

  • Lipopolysaccharides
  • Polymorphism (genetics)
  • Risk factors
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Ito, D., Murata, M., Tanahashi, N., Sato, H., Sonoda, A., Saito, I., ... Fukuuchi, Y. (2000). Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke, 31(11), 2661-2664.

Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. / Ito, Daisuke; Murata, Mitsuru; Tanahashi, Norio; Sato, Hideki; Sonoda, Akira; Saito, Ikuo; Watanabe, Kiyoaki; Fukuuchi, Yasuo.

In: Stroke, Vol. 31, No. 11, 2000, p. 2661-2664.

Research output: Contribution to journalArticle

Ito, D, Murata, M, Tanahashi, N, Sato, H, Sonoda, A, Saito, I, Watanabe, K & Fukuuchi, Y 2000, 'Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease', Stroke, vol. 31, no. 11, pp. 2661-2664.
Ito, Daisuke ; Murata, Mitsuru ; Tanahashi, Norio ; Sato, Hideki ; Sonoda, Akira ; Saito, Ikuo ; Watanabe, Kiyoaki ; Fukuuchi, Yasuo. / Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. In: Stroke. 2000 ; Vol. 31, No. 11. pp. 2661-2664.
@article{21030dd41fce468cbd9540cbe98dfb5c,
title = "Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease",
abstract = "Background and Purpose - A growing amount of evidence suggests that infectious and inflammatory processes may be involved in the initiation of arteriosclerosis, but the mechanisms are conceivably multifactorial and complex. Two European groups have recently demonstrated that a C(-260)→T polymorphism in the promoter of the CD14 lipopolysaccharide receptor may be a risk factor for coronary artery disease (CAD). The T allele of this polymorphism reportedly increases the expression of CD14 and may be involved in atherogenesis. In the present study we investigated a possible association between the C(-260)→T polymorphism in the CD14 promoter and the occurrence of symptomatic ischemic cerebrovascular disease (CVD). Methods - Genotype frequencies of the C(-260)→T polymorphism in the CD14 promoter were determined in 235 patients with CVD, as confirmed by brain CT and/or MRI, and 309 age- and sex-matched control subjects. Results - The distribution of genotypes was as follows: CVD patients, T/T 24.3{\%}, C/T 53.2{\%}, and C/C 22.6{\%}; controls, T/T 26.9{\%}, C/T 50.2{\%}, and C/C 23.0{\%}. There was no significant difference between the CD14 promoter genotypes of the CVD patients and the controls (χ2=0.601, P=0.741). We also measured the concentration of serum soluble CD14 and the density of membranous CD14 on monocytes in the CVD patients, but the polymorphism was not associated with either the concentration of soluble CD14 or the density of membranous CD14 (P=0.358, P=0.238, respectively). Conclusions - Our results indicate that the C(-260)→T polymorphism in the CD14 promoter is not associated with an increased risk for CVD.",
keywords = "Lipopolysaccharides, Polymorphism (genetics), Risk factors, Stroke",
author = "Daisuke Ito and Mitsuru Murata and Norio Tanahashi and Hideki Sato and Akira Sonoda and Ikuo Saito and Kiyoaki Watanabe and Yasuo Fukuuchi",
year = "2000",
language = "English",
volume = "31",
pages = "2661--2664",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease

AU - Ito, Daisuke

AU - Murata, Mitsuru

AU - Tanahashi, Norio

AU - Sato, Hideki

AU - Sonoda, Akira

AU - Saito, Ikuo

AU - Watanabe, Kiyoaki

AU - Fukuuchi, Yasuo

PY - 2000

Y1 - 2000

N2 - Background and Purpose - A growing amount of evidence suggests that infectious and inflammatory processes may be involved in the initiation of arteriosclerosis, but the mechanisms are conceivably multifactorial and complex. Two European groups have recently demonstrated that a C(-260)→T polymorphism in the promoter of the CD14 lipopolysaccharide receptor may be a risk factor for coronary artery disease (CAD). The T allele of this polymorphism reportedly increases the expression of CD14 and may be involved in atherogenesis. In the present study we investigated a possible association between the C(-260)→T polymorphism in the CD14 promoter and the occurrence of symptomatic ischemic cerebrovascular disease (CVD). Methods - Genotype frequencies of the C(-260)→T polymorphism in the CD14 promoter were determined in 235 patients with CVD, as confirmed by brain CT and/or MRI, and 309 age- and sex-matched control subjects. Results - The distribution of genotypes was as follows: CVD patients, T/T 24.3%, C/T 53.2%, and C/C 22.6%; controls, T/T 26.9%, C/T 50.2%, and C/C 23.0%. There was no significant difference between the CD14 promoter genotypes of the CVD patients and the controls (χ2=0.601, P=0.741). We also measured the concentration of serum soluble CD14 and the density of membranous CD14 on monocytes in the CVD patients, but the polymorphism was not associated with either the concentration of soluble CD14 or the density of membranous CD14 (P=0.358, P=0.238, respectively). Conclusions - Our results indicate that the C(-260)→T polymorphism in the CD14 promoter is not associated with an increased risk for CVD.

AB - Background and Purpose - A growing amount of evidence suggests that infectious and inflammatory processes may be involved in the initiation of arteriosclerosis, but the mechanisms are conceivably multifactorial and complex. Two European groups have recently demonstrated that a C(-260)→T polymorphism in the promoter of the CD14 lipopolysaccharide receptor may be a risk factor for coronary artery disease (CAD). The T allele of this polymorphism reportedly increases the expression of CD14 and may be involved in atherogenesis. In the present study we investigated a possible association between the C(-260)→T polymorphism in the CD14 promoter and the occurrence of symptomatic ischemic cerebrovascular disease (CVD). Methods - Genotype frequencies of the C(-260)→T polymorphism in the CD14 promoter were determined in 235 patients with CVD, as confirmed by brain CT and/or MRI, and 309 age- and sex-matched control subjects. Results - The distribution of genotypes was as follows: CVD patients, T/T 24.3%, C/T 53.2%, and C/C 22.6%; controls, T/T 26.9%, C/T 50.2%, and C/C 23.0%. There was no significant difference between the CD14 promoter genotypes of the CVD patients and the controls (χ2=0.601, P=0.741). We also measured the concentration of serum soluble CD14 and the density of membranous CD14 on monocytes in the CVD patients, but the polymorphism was not associated with either the concentration of soluble CD14 or the density of membranous CD14 (P=0.358, P=0.238, respectively). Conclusions - Our results indicate that the C(-260)→T polymorphism in the CD14 promoter is not associated with an increased risk for CVD.

KW - Lipopolysaccharides

KW - Polymorphism (genetics)

KW - Risk factors

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0033760793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033760793&partnerID=8YFLogxK

M3 - Article

C2 - 11062291

AN - SCOPUS:0033760793

VL - 31

SP - 2661

EP - 2664

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 11

ER -